// App-Quantinova.ai

1606 : Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Koji Sasaki

Principal Investigators

  • Susan M. -Brien

  • Nitin Jain

  • Marina Konopleva

  • Richard E. Champlin

  • Issa F. Khouri

  • Partow Kebriaei

  • David Marin

  • Courtney D. DiNardo

  • Zeev Estrov

  • Koichi Takahashi

  • Nicholas J. Short

  • Farhad Ravandi

  • Maria R. Khouri

  • Jovitta Jacob

  • Rebecca Garris

  • Jorge E. Cortes

  • Hagop M. Kantarjian

  • Deborah A Thomas

  • Tapan M. Kadia

  • Guillermo Garcia-Manero

  • Jan A. Burger

  • Naveen Pemmaraju

  • Yesid Alvarado

  • Naval G. Daver

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Methotrexate

  • Cytarabine liposomal

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved